Clinical Trials
11 trialsNCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03367871 2024-06-18
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Phase 2 Terminated
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT02921269 2023-02-21
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025233 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Phase 2 Completed
NCT00803062 2019-07-23
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00369122 2018-03-20
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00545792 2017-03-15
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00548418 2014-08-01
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00626561 2014-07-07
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
M.D. Anderson Cancer Center
Phase 2 Terminated